Comparing Pieris Pharmaceuticals (PIRS) & Syneos Health (SYNH)

Pieris Pharmaceuticals (NASDAQ: PIRS) and Syneos Health (NASDAQ:SYNH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Pieris Pharmaceuticals and Syneos Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -65.40% -96.56% -15.25%
Syneos Health -5.50% 8.79% 3.53%

Volatility & Risk

Pieris Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Syneos Health has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

62.9% of Pieris Pharmaceuticals shares are owned by institutional investors. 4.1% of Pieris Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Syneos Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Pieris Pharmaceuticals and Syneos Health’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pieris Pharmaceuticals $25.27 million 12.90 -$17.64 million ($0.40) -15.10
Syneos Health $2.67 billion 1.63 -$138.46 million $1.94 21.78

Pieris Pharmaceuticals has higher earnings, but lower revenue than Syneos Health. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Syneos Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Pieris Pharmaceuticals and Syneos Health, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 6 0 3.00
Syneos Health 0 3 8 0 2.73

Pieris Pharmaceuticals presently has a consensus target price of $11.50, suggesting a potential upside of 90.40%. Syneos Health has a consensus target price of $50.78, suggesting a potential upside of 20.18%. Given Pieris Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Pieris Pharmaceuticals is more favorable than Syneos Health.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

About Syneos Health

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply